<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML><HEAD><TITLE>Johnson &amp; Johnson Clinical Trials in tranSMART Search</TITLE>
<META content="text/html; charset=us-ascii" http-equiv=Content-Type><LINK 
rel=stylesheet type=text/css href="../Theme/nav.css"><LINK rel=stylesheet 
type=text/css href="../Theme/popupmenu.css"><LINK rel=stylesheet type=text/css 
href="../Theme/lf.css"><LINK rel=stylesheet type=text/css 
href="../LinksExt/doc2help.css"><LINK rel=stylesheet type=text/css 
href="../LinksExt/tranSMART_RN.css">
<SCRIPT type=text/javascript>



var _needIndentation = false;



</SCRIPT>

<SCRIPT language=JavaScript src="../linker.js">

</SCRIPT>

<SCRIPT language=JavaScript src="../special.js">

</SCRIPT>

<SCRIPT language=JavaScript src="../common.js">

</SCRIPT>

<meta name="Generator" content="ComponentOne Doc-To-Help v.2011.1.0.614">
<meta name="D2HTheme" content="(Default) v.146">
</HEAD>
<BODY 
style="PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #535353; MARGIN: 7px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; OVERFLOW: hidden; PADDING-TOP: 0px" 
onload=d2hOnLoadToolbar(event); relPart="../">
<SCRIPT language=javascript>



d2hTopicPreOpen();



d2hTrySyncTOC();







var prev = true;





var next = true;



if (typeof d2hInitMainThemeHandlers != "undefined")

    d2hInitMainThemeHandlers(prev, next);

d2hAdjustTopicBorders(document);    



if (typeof d2hLoadWindows != "undefined")

    d2hLoadWindows();

if (typeof d2hLoadNavUrls != "undefined")

    d2hLoadNavUrls();



</SCRIPT>

<DIV 
style="PADDING-BOTTOM: 0px; BACKGROUND-COLOR: white; MARGIN: 0px; PADDING-LEFT: 0px; WIDTH: 100%; PADDING-RIGHT: 0px; HEIGHT: 100%; OVERFLOW: auto; PADDING-TOP: 0px" 
id=D2HTopicOuterBody class=d2h_outer_topic>
<DIV id=nsbanner class=d2hNavigatorTopic>
<DIV 
style="PADDING-BOTTOM: 0px; PADDING-LEFT: 0px; PADDING-RIGHT: 0px; PADDING-TOP: 0px" 
id=TitleRow class=d2h_main_titlerow>
<DIV style="DISPLAY: none"><A id=D2HPreviousAnchor 
href="trialsandstudiesindatasetexplorer.htm"></A><A id=D2HNextAnchor 
href="resolveddefects.htm"></A></DIV></DIV>
<SCRIPT language=javascript>

if (typeof d2hProcessTopicNavForCSH != "undefined")

    d2hProcessTopicNavForCSH();

</SCRIPT>
</DIV>
<DIV 
style="PADDING-BOTTOM: 10px; PADDING-LEFT: 22px; PADDING-RIGHT: 10px; HEIGHT: 100%; PADDING-TOP: 5px" 
id=nstext class=d2h_main_nstext valign="bottom">
<DIV id=d2h_breadcrumbs class=d2h_breadcrumbs><SPAN 
class=d2h_breadcrumbsLabel><B><SPAN style="COLOR: #000080">Release 
Notes</SPAN></B>&nbsp;&nbsp;</SPAN><A class=d2h_breadcrumbsNormal 
href="transmartreleasenotes.htm">tranSMART Release Notes</A></DIV>
<H2><A name=_Toc242498269></A><A name=_Toc283129530></A><A 
name=_Toc251842385>Johnson &amp; Johnson Clinical Trials in tranSMART 
Search</A></H2>
<P style="PAGE-BREAK-AFTER: avoid" class=MsoNormal><SPAN 
style="COLOR: black">The following table shows the list of Johnson &amp;&nbsp; 
Johnson clinical trials that can be included in a tranSMART search 
result.</SPAN></P>
<TABLE 
style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; BORDER-COLLAPSE: collapse; MARGIN-LEFT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: medium none" 
class=tranSMARTTable border=1 cellSpacing=0 cellPadding=0 width=583>
  <THEAD>
  <TR>
    <TD 
    style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    width=86>
      <P style="PAGE-BREAK-AFTER: avoid; MARGIN-BOTTOM: 6pt" 
      class=TableHeading><SPAN 
      style="COLOR: black; FONT-SIZE: 8pt">Trial</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1.5pt solid; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    width=314>
      <P style="PAGE-BREAK-AFTER: avoid; MARGIN-BOTTOM: 6pt" 
      class=TableHeading><SPAN 
      style="COLOR: black; FONT-SIZE: 8pt">Title</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: windowtext 1.5pt solid; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    width=183>
      <P style="PAGE-BREAK-AFTER: avoid; MARGIN-BOTTOM: 6pt" 
      class=TableHeading><SPAN 
      style="COLOR: black; FONT-SIZE: 8pt">Platform</SPAN></P></TD></TR></THEAD>
  <TBODY>
  <TR style="PAGE-BREAK-INSIDE: avoid; HEIGHT: 28.35pt">
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; HEIGHT: 28.35pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=86>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">C0168T37</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; HEIGHT: 28.35pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=314>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">A Randomized, Placebo-controlled, 
      Double-blind Trial to Evaluate the Safety and Efficacy of Infliximab in 
      Patients with Active Ulcerative Colitis.</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; HEIGHT: 28.35pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=183>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array</SPAN></P></TD></TR>
  <TR style="PAGE-BREAK-INSIDE: avoid">
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=86>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">C0168T44</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=314>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">A Phase III, Multicenter, Randomized, 
      Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety 
      of Infliximab Induction Therapy Followed by Multiple Regimens of 
      Maintenance Infliximab Therapy in Subjects with Plaque-type 
      Psoriasis.</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=183>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array</SPAN></P></TD></TR>
  <TR style="PAGE-BREAK-INSIDE: avoid">
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=86>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">C0168T48</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=314>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">A Multicenter, Randomized, 
      Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy 
      of Infliximab (REMICADE&reg;) in Subjects with Chronic Sarcoidosis with 
      Pulmonary Involvement.</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=183>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">RBM</SPAN></P></TD></TR>
  <TR style="PAGE-BREAK-INSIDE: avoid">
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=86>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">C0379T02</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=314>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">A Phase I, Double-blind, 
      Placebo-controlled Study Evaluating the Safety and Pharmacology of Single 
      Subcutaneous Administrations of Human Monoclonal Antibody to IL-12 (CNTO 
      1275) in Subjects with Moderate to Severe Psoriasis 
Vulgaris.</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=183>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">DNA</SPAN></P></TD></TR>
  <TR style="PAGE-BREAK-INSIDE: avoid">
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=86>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">C0379T03</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=314>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">A Phase I, Double-blind, 
      Placebo-controlled Study Evaluating the Safety and Pharmacology of Single 
      Subcutaneous Administrations of Human Monoclonal Antibody to IL-12 (CNTO 
      1275) in Subjects with Relapsing Forms of Multiple 
Sclerosis.</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=183>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">DNA</SPAN></P></TD></TR>
  <TR style="PAGE-BREAK-INSIDE: avoid">
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=86>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">C0379T07</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=314>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">A Multicenter, Randomized, Phase 2a 
      Study of Human Monoclonal Antibody to IL-12p40 (CNTO 1275) in Subjects 
      With Moderately to Severely Active Crohn&#8217;s Disease.</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=183>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array</SPAN></P></TD></TR>
  <TR style="PAGE-BREAK-INSIDE: avoid">
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=86>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">C0524T03</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=314>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">A Phase 2, Multicenter, Randomized, 
      Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study 
      Evaluating the Efficacy and Safety Of CNTO 148 Administered Subcutaneously 
      in Symptomatic Subjects With Severe Persistent Asthma.</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=183>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array</SPAN></P></TD></TR>
  <TR style="PAGE-BREAK-INSIDE: avoid">
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=86>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">C0743T10</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=314>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">A Phase 2, Multicenter, Randomized, 
      Double-blind, Placebo-controlled Trial of CNTO 1275, a Fully Human 
      Anti-IL-12 Monoclonal Antibody, Administered Subcutaneously, in Subjects 
      with Active Psoriatic Arthritis.</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=183>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">RBM</SPAN></P></TD></TR>
  <TR style="PAGE-BREAK-INSIDE: avoid">
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=86>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">C0743T12</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=314>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">A Phase 3, Multicenter, Randomized 
      Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to 
      Severe Plaque Psoriasis.</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: black 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=183>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array</SPAN></P></TD></TR>
  <TR style="PAGE-BREAK-INSIDE: avoid">
    <TD 
    style="BORDER-BOTTOM: windowtext 1.5pt solid; BORDER-LEFT: windowtext 1.5pt solid; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 64.3pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=86>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">C0743X01</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: windowtext 1.5pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 235.7pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: black 1pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=314>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">Detection of Mediators of Sarcoidosis 
      Skin Lesions.</SPAN></P></TD>
    <TD 
    style="BORDER-BOTTOM: windowtext 1.5pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0pt; PADDING-LEFT: 5.4pt; WIDTH: 137.4pt; PADDING-RIGHT: 5.4pt; BORDER-TOP: medium none; BORDER-RIGHT: windowtext 1.5pt solid; PADDING-TOP: 0pt" 
    vAlign=top width=183>
      <P style="MARGIN: 6pt 0pt" class=MsoNormal><SPAN 
      style="COLOR: black; FONT-SIZE: 9pt">Affymetrix Human Genome U133 Plus 2.0 
      array, RBM</SPAN></P></TD></TR></TBODY></TABLE></DIV></DIV></BODY></HTML>
